Biotech entrepreneur Romesh Subramanian has launched Marrow Therapeutics, a Watertown-based startup focusing on new treatments for sickle cell disease. The company announced Tuesday that it has secured $173 million in Series A and B funding from investors including Scion Life Sciences, venBio, and OrbiMed to support its development efforts.
Sickle cell disease is caused by mutations in the gene responsible for hemoglobin, the molecule that carries oxygen in red blood cells. Current gene-editing therapies, such as those developed by CRISPR Therapeutics and Vertex Pharmaceuticals, work by activating fetal hemoglobin—a form typically produced only in early development—through targeted editing of the BCL11A gene. This method requires extracting patients’ blood cells, editing them outside the body, and reinfusing them following chemotherapy. While effective, this process is costly, intensive, and carries significant risks including infertility, other serious side effects, and, in rare cases, death. Additionally, eligibility for this therapy is limited to certain patients in the United States and Europe. The treatment is not currently accessible in regions with the highest burden of the disease, such as sub-Saharan Africa.
Subramanian aims to develop an alternative treatment that matches the efficacy of gene-editing therapies but reduces the associated drawbacks. Instead of employing permanent gene edits, Marrow Therapeutics is pursuing a strategy using short interfering RNA (siRNA), which can temporarily silence specific genes. This approach could potentially simplify treatment delivery and lower risks compared to existing methods.
While efforts to develop non-gene editing treatments—such as pills or infusions that activate fetal hemoglobin without the need for complex procedures—have faced challenges, early research provides some optimism, especially with CRISPR-based treatments designed for direct infusion into the bloodstream.
Marrow Therapeutics’ approach represents a novel direction amid ongoing efforts to find more accessible and safer therapies for sickle cell disease. Subramanian expressed confidence in the company’s potential to offer a treatment with comparable effectiveness to gene therapy, pending clinical validation. The startup’s progress will be closely watched as it advances its siRNA platform and works toward addressing the unmet needs of patients worldwide.
